Biotechnology & Life Sciences
Finance leadership at the intersection of science and business.
David is Chief Financial Officer of FairJourney Biologics, an international biotechnology Contract Research Organisation specialising in antibody discovery and engineering.
Current role
CFO, FairJourney Biologics.
In a CRO, the business model, the science and the client relationship are tightly linked. Financial leadership means understanding how research programmes are scoped and delivered, how capacity and capabilities are built, and how a scientific services company scales internationally while protecting quality and margins.
David works where research innovation, business models, strategic finance and commercialisation meet, translating scientific activity into financial performance, investment decisions and long-term value.
The CRO and drug discovery ecosystem
Understanding the strategic and commercial implications of scientific innovation.
CRO business models
Fee-for-service, integrated programmes and partnerships: how scientific services create and capture value.
Research operations
Linking laboratory operations, capacity and project delivery to financial performance.
Partnering & collaboration
How biotech companies, pharmaceutical companies and technology platforms work together.
Areas of interest
Where the field is heading.
AI-native biotech
Companies built around computation from the start, and how their economics differ.
Antibody discovery & engineering
The core of FairJourney Biologics' work, from discovery to optimisation.
Multispecific antibodies
Molecules engaging more than one target, and the complexity they bring to R&D.
Antibody-drug conjugates
A fast-growing modality combining biologics with targeted payloads.
Immunology
A major area of therapeutic innovation and partnering activity.
Next-generation discovery technologies
Platforms that change the speed, cost and success rate of discovery.
Let's connect